Dianthus (DNTH) CFO exercises options and sells shares under 10b5-1 plan
Rhea-AI Filing Summary
Insider transactions at Dianthus Therapeutics (DNTH): Chief Financial & Business Officer Ryan Savitz executed and sold shares under a Rule 10b5-1 plan on 09/09/2025. He exercised a stock option to buy 20,000 shares at a $8.44 exercise price and simultaneously sold 20,000 shares at $35 per share. After these transactions, the reporting person beneficially owns 104,766 shares of common stock. The option award underlying the exercise vests over time, with 25% vested on 06/02/2023 and the remainder vesting monthly over the following three years. The filing was signed by an attorney-in-fact on 09/11/2025.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating the sale was pre-planned and provides an affirmative defense for the insider
- Exercise price of $8.44 vs sale price of $35 shows the executive captured a significant spread on vested options
Negative
- Insider sale of 20,000 shares could be viewed negatively by some investors as insider monetization, though it was pre-planned
- No company-wide context provided in the filing to gauge the relative size or timing impact of the transaction on overall insider ownership
Insights
TL;DR: Routine option exercise and sale under a pre-established 10b5-1 plan; no indication of new company-specific material information.
This Form 4 reports a pre-planned exercise and contemporaneous sale by an executive using a Rule 10b5-1 trading plan adopted March 31, 2025. Such plans are commonly used to mitigate insider trading concerns and provide an affirmative defense under Rule 10b5-1. The disclosure includes vesting details for the option award, indicating standard time-based vesting that began June 2, 2023. From a governance perspective, the filing is compliant and transparent about the plan and vesting.
TL;DR: Executive monetized vested options at a substantially higher market price than the strike; transaction appears routine and non-disruptive.
The reporting person exercised 20,000 option shares at $8.44 and sold 20,000 shares at $35, realizing the spread between exercise price and sale price. Post-transaction beneficial ownership is 104,766 shares, which remains meaningful but requires company-wide context to assess materiality. The use of a 10b5-1 plan reduces timing concerns; absent other disclosures, this is a standard insider liquidity event rather than a signal of material corporate change.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 20,000 | $8.44 | $169K |
| Sale | Common Stock | 20,000 | $35.00 | $700K |
Footnotes (1)
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
